Abstract
In patients with intermediate or high grade non-Hodgkin lymphoma (NHL), third generation chemotherapy regimens have been introduced to improve survival in comparison with the standard CHOP regimen. However, most studies have found no difference between these two treatments. We conducted a meta-analysis to assess the effectiveness of third generation regimens as compared with CHOP. Our study included the randomized controlled trials published in English from 1970 to 1999. After a Medline search, 5 trials were found to meet our inclusion criteria. A total of 1982 patients, that were enrolled in these trials, were included in the survival meta-analysis. Our methodology retrieved patient-level information from all of these subjects; survival up to 9 years after randomization was compared between the two treatment options. The results of our meta-analysis showed that, in comparison with CHOP, third generation chemotherapy did not prolong survival at levels of statistical significance (chi-square by log-rank test = 1.44, P = 0.23). The relative death risk for third generation regimens vs. CHOP was 0.92 (95%CI: 0.80 to 1.06;P =0.26). We conclude that, on the basis of our meta-analysis, third generation regimens do not confer any survival benefit to patients with intermediate or high grade NHL as compared with CHOP. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bardelli F, Messori A, Rampazzo R, Alberti A and Martini N (1995) Effect of recombinant or lymphoblastoid alpha interferon on ALT in patients with chronic hepatitis C or chronic non-A non-B hepatitis: a meta-analysis. Clin Drug Invest 9: 239–254
Collins R, Yusuf S and Peto R (1985) Overview of randomised trials of diuretics in pregnancy. BMJ 290: 17–23
Cooper IA, Wolf MM, Robertson TI, Fox RM, Matthews JP, Stone JM, Chong Ding J, Dart G, Matthews J, Firkin FC, Lowenthal RM and Ironside P (1994) Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin’s lymphoma. J Clin Oncol 12: 769–778
Edmiston CE, Josephson A, Pottinger J, Ciacco-Tsivitis M and Palenik C (1993) The numbers game: sample-size determination. Am J Infect Control 3: 151–154
Ferrandina G, Scambia G, Bardelli F, Benedetti Panici P, Mancuso S and Messori A (1997) Relationship between cathepsin-D content and disease-free survival in node-negative breast cancer patients: a meta-analysis. Br J Cancer 76: 661–666
Fine HA, Dear KBG, Loeffler JS, Black PML and Canellos GP (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71: 2585–2592
Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA and Miller TP (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 328: 1002–1006
Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F, Gandola L, Tarella C, Pileri A, Ravagnani F, Valagussa P and Bonadonna G (1997) High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 336: 1290–1297
Goldie JH, Coldman AJ and Gudauskas GA (1982) Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 66: 439–449
Gordon LI, Harrington D, Andersen J, Colgan J, Glick J, Neiman R, Mann R, Resnick GD, Barcos M, Gottlieb A and O’Connell M (1992) Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin’s lymphoma. N Engl J Med 327: 1342–1349
Guglielmi C, Gherlinzoni F, Amadori S, Mazza P, Mantovani L, Lauria F, Martelli M, Zinzani PL, Greco V and Poletti G (1989) A phase III comparative trial of m-BACOD vs m-BNCOD in the treatment of stage II–IV diffuse non-Hodgkin’s lymphomas. Haematologica 74: 563–569
Jeng GT, Scott JR and Burmeister LF (1995) A comparison of meta-analytic results using literature vs individual patient data: paternal cell immunization for recurrent miscarriage. JAMA 274: 830–836
Jerkeman M, Anderson H, Cavallin-Stahl E, Dictor M, Hagberg H, Johnson A, Kaasa S, Kvaloy S, Sundström C and Åkerman M (1999) CHOP versus MACOP-B in aggressive lymphoma – a Nordic Lymphoma Group randomised trial. Ann Oncol 10: 1079–1086
Linch DC, Vaughan Hudson B, Hancock BW, Hoskin PJ, Cunningham DC, Newland AC, Milligan DW, Stevenson PA, Wood JK, MacLennan KA, Anderson L, Gregory WM, Vaughan, and Hudson G (1996) A randomised comparison of a third generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin’s lymphoma: a British National Lymphoma Investigation report. Br J Cancer 74: 318–322
Martelli M, De Sanctis Vitaliana, Avvisati G and Mandelli F (1997) Current guidelines for the management of aggressive non-Hodgkin’s lymphoma. Drugs 53: 957–972
Mazza P and Zinzani PL (1995) MACOP-B vs. F-MACHOP regimen in the treatment of high-grade non-Hodgkin’s lymphomas. Leuk Lymphoma 16: 457–463
Messori A and Rampazzo R (1993) Meta-analysis of clinical trials based on censored end-points: simplified theory and implementation of the statistical algorithms on a microcomputer. Comput Progr Meth Biomed 40: 261–267
Messori A, Brignola C, Trallori G, Rampazzo R, Bardazzi G, Belloli C, d’Albasio G, De Simone G and Martini N (1994) Effectiveness of 5-aminosalicylic acid (5-ASA) for maintaining remission in patients with Crohn’s disease: a meta-analysis. Am J Gastroenterol 89: 692–698
Messori A, Bosi A, Bacci S, Laszlo D, Trippoli S, Locatelli F, Van Lint MT and Di Bartolomeo P Amici A on behalf of the GITMO (1999a) Retrospective survival analysis and cost-effectiveness evaluation of second allogeneic bone marrow transplantation in patients with acute leukemia. Bone Marrow Transplant 23: 489–495
Messori A, Trippoli S, Becagli P and Zaccara G (1999b) Cost-effectiveness of riluzole in amyotrophic lateral sclerosis. Pharmacoeconomics 16: 153–163
Messori A, Trippoli G, Vaiani M and Cattel F (2000) Survival meta-analysis of individual patient data and survival meta-analysis of published (aggregate) data. Clin Drug Invest 20: 309–316
Montserrat E, Vinolas N, Lopez-Guillermo A, Hernandez-Nieto L, Zubizarreta A, Maldonado J, Alcala A, Faura MV, Llorente A, Bladé J, Fontanillas M and Estap, (1996) CHOP vs. ProMACE-CytaBOM in the treatment of aggressive non-Hodgkin’s lymphomas: long-term results of a multicenter randomized trial. Eur J Haematol 57: 377–383
Oxman AD, Clarke MJ and Stewart LA (1995) From science to practice: meta-analysis using individual patient data are needed. JAMA 274: 845–846
Steinberg KK, Smith SJ, Stroup DF, Olkin I, Lee NC, Williamson GD and Thacker SB (1997) Comparison of effect estimates from a meta-analysis of summary data from published studies and from a meta-analysis using individual patient data for ovarian cancer studies. Am J Epidemiol 145: 917–925
Stewart LA and Parmar MK (1993) Meta-analysis of the literature or of individual patient data: is there a difference?. Lancet 341: 418–422
Trallori G, Messori A, Scuffi C, Bardazzi G, Silvano R, d’Albasio G and Pacini F (1995) Effectiveness of 5-aminosalicylic acid enemas for maintaining remission in patients with left-sided ulcerative colitis: a meta- and economic analysis. J Clin Gastroenterol 20: 257–259
Wolf M, Matthews JP, Stone J, Cooper IA, Robertson TI and Fox RM (1997) Long-term survival advantage of MACOP-B over CHOP in intermediate-grade non-Hodgkin’s lymphoma. Ann Oncol 8 (Suppl.1): S71–S75
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Messori, A., Vaiani, M., Trippoli, S. et al. Survival in patients with intermediate or high grade non-Hodgkin’s lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP. Br J Cancer 84, 303–307 (2001). https://doi.org/10.1054/bjoc.2000.1566
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1566
Keywords
This article is cited by
-
First-line treatments for chronic lymphocytic leukaemia: interpreting efficacy data by network meta-analysis
Annals of Hematology (2015)
-
Phase I trial examining addition of gemcitabine to CHOP in intermediate grade NHL
Cancer Chemotherapy and Pharmacology (2011)
-
Analysis of efficacy of DICE (dexamethasone, ifosfamide, cisplatin and etoposide) regimen on recurrent and refractory intermediate and high grade non-Hodgkin’s lymphoma
Chinese Journal of Clinical Oncology (2009)
-
Clinical randomized comparative trial of DICE regimen and CHOP regimen in treating intermediate and high grade non-Hodgkin’s lymphoma
The Chinese-German Journal of Clinical Oncology (2008)
-
Current trends in large cell lymphoma
Leukemia (2003)